Granta Park-based Nxera Pharma has received a $15million milestone payment after its partner, Neurocrine Biosciences, dosed ...

Medical Devices & Diagnostics Analysts, along with Dr. Jolie Chang, Chief of Sleep Surgery Division at UCSF, discuss 2Q25 sleep medicine trends ...

Shares in MaaT Pharma (Euronext: MAAT), a French microbiome company in oncology, closed 25% higher Tuesday. The company ...

Japanese biotech Nxera Pharma (TSE: 4565) has received a $15 million payment from Neurocrine Biosciences (Nasdaq: NBIX) after ...

Cambridge UK and Tokyo biopharma business Nxera Pharma has hauled in $15 million after partner Neurocrine Biosciences dosed the first patient in its Phase 3 registrational programme of NBI-1117568 ...

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences ...

Nxera Pharma has announced a significant development milestone in its multi-target collaboration with Eli Lilly, marking a ...

Broadcom is set to report its second-quarter results, with Wall Street anticipating a 20% revenue boost, driven by ...

Nxera Pharma just hit a milestone in its collaboration with Eli Lilly, unlocking a confidential payment expected by late 2025. This achievement significantly boosts Nxera’s research efforts in ...

(RTTNews) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY) targeting diabetes and ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone ...